Journal Article

Effects of Formulation and Dosing Strategy on Amprenavir Concentrations in the Seminal Plasma of Human Immunodeficiency Virus Type 1-Infected Men

Naumann I. Chaudry, Joseph J. Eron, Odin J. Naderer, Arlene S. Pereira, M. B. Wire, Susan A. Fiscus and Angela D. M. Kashuba

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 35, issue 6, pages 760-762
Published in print September 2002 | ISSN: 1058-4838
Published online September 2002 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/342389
Effects of Formulation and Dosing Strategy on Amprenavir Concentrations in the Seminal Plasma of Human Immunodeficiency Virus Type 1-Infected Men

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

We compared seminal plasma pharmacokinetic data for the investigational amprenavir prodrug GW433908 with those for amprenavir and an amprenavir-ritonavir combination regimen. All 3 regimens resulted in detectable blood plasma and seminal plasma concentrations of amprenavir. The majority of these concentrations were greater than the plasma protein-corrected 50% inhibitory concentration for wild-type human immunodeficiency virus type 1.

Journal Article.  1893 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.